Neonatal screening for severe combined immunodeficiency caused by an adenosine deaminase defect: A reliable and inexpensive method using tandem mass spectrometry

Journal of Allergy and Clinical Immunology

Volumn 127, Issue 6, 2011, Pages 1394-1399

  Azzari, Chiara ^a   La Marca, Giancarlo ^a,b   Resti, Massimo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Adenosine deaminase; newborn screening; severe combined immunodeficiency; tandem mass spectrometry

Indexed keywords

ADENOSINE; DEOXYADENOSINE;

ADENOSINE DEAMINASE DEFICIENCY; ADULT; ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; CASE REPORT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRIED BLOOD SPOT SAMPLE; ENZYME BLOOD LEVEL; HEALTH CARE COST; HUMAN; HUMAN TISSUE; LABORATORY DIAGNOSIS; NEWBORN; NEWBORN DISEASE; NEWBORN SCREENING; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; SEVERE COMBINED IMMUNODEFICIENCY; TANDEM MASS SPECTROMETRY;

ADENOSINE; ADENOSINE DEAMINASE; AGAMMAGLOBULINEMIA; BLOOD CHEMICAL ANALYSIS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COSTS AND COST ANALYSIS; DEOXYADENOSINES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; ITALY; MALE; NEONATAL SCREENING; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERE COMBINED IMMUNODEFICIENCY; TANDEM MASS SPECTROMETRY;

EID: 79957794697     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2011.03.040     Document Type: Article

References (25)

1. Puck JM. SCID Newborn Screening Working Group. Population-based newborn screening for severe combined immunodeficiency: steps toward implementation. J Allergy Clin Immunol 2007;120:760-8. (Pubitemid 47542285)
2. Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol 2004;22:625-55. (Pubitemid 38680436)
3. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol 2010; 125(suppl 2):S182-94.
4. Sauer AV, Aiuti A. New insights into the pathogenesis of adenosine deaminasesevere combined immunodeficiency and progress in gene therapy. Curr Opin Allergy Clin Immunol 2009;9:496-502.
5. Hirschhorn R. Adenosine deaminase deficiency. Immunodefic Rev 1990;2:175-98.
6. Booth C, Hershfield M, Notarangelo L, Buckley R, Hoenig M, Mahlaoui N, et al. Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006). Clin Immunol 2007;123: 139-47. (Pubitemid 46590067)
7. Sanchez JJ, Monaghan G, Børsting C, Norbury G, Morling N, Gaspar HB. Carrier frequency of a nonsense mutation in the adenosine deaminase (ADA) gene implies a high incidence of ADA-deficient severe combined immunodeficiency (SCID) in Somalia and a single, common haplotype indicates common ancestry. Ann Hum Genet 2007;71(suppl):336-47.
8. Gaspar BH, Aiuti A, Porta F, Candotti F, Hershfield MS, Notarangelo LD. How I treat ADA deficiency. Blood 2009;114:3524-32.
9. Hershfield MS, Mitchell BS. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill; 1995. p. 1725-68.
10. Chace DH. Mass spectrometry in newborn and metabolic screening: historical perspective and future directions. J Mass Spectrom 2009;44:163-70.
11. la Marca G, Malvagia S, Pasquini E, Innocenti M, Donati MA, Zammarchi E. Rapid 2nd-tier test for measurement of 3-OH-propionic and methylmalonic acids on dried blood spots: reducing the false-positive rate for propionylcarnitine during expanded newborn screening by liquid chromatography-tandem mass spectrometry. Clin Chem 2007;53:1364-9. (Pubitemid 47020995)
12. la Marca G, Malvagia S, Pasquini E, Innocenti M, Fernandez MR, Donati MA, et al. The inclusion of succinylacetone as marker for tyrosinemia type I in expanded newborn screening programs. Rapid Commun Mass Spectrom 2008;22:812-8. (Pubitemid 351442555)
13. Health Resources and Services Administration. Secretary's Advisory Committee on Heritable Disorders in Newborns and Children. Resolution from the 20th meeting, January 22, 2010; Washington DC. Available at: http://www.hrsa.gov/heritabledisorderscommittee/. Accessed April 29, 2011.
14. Howell RR, Engelson G. Structures for clinical follow-up: newborn screening. J Inherit Metab Dis 2007;30:600-5. (Pubitemid 47377057)
15. Lipstein EA, Vorono S, Browning MF, Green NS, Kemper AR, Knapp AA, et al. Systematic evidence review of newborn screening and treatment of severe combined immunodeficiency. Pediatrics 2010;125:e1226-35.
16. Morgan G, Levinsky RJ, Hugh-Jones K, Fairbanks LD, Morris GS, Simmonds HA. Heterogeneity of biochemical, clinical and immunological parameters in severe combined immunodeficiency due to adenosine deaminase deficiency. Clin Exp Immunol 1987;70:491-9. (Pubitemid 18013186)
17. Hirschhorn R, Borkowsky W, Jiang CK, Yang DR, Jenkins T. Two newly identified mutations (Thr233Ile and Leu152Met) in partially adenosine deaminase-deficient (ADA-) individuals that result in differing biochemical and metabolic phenotypes. Hum Genet 1997;100:22-9.
18. Santisteban I, Arredondo-Vega FX, Kelly S, Mary A, Fischer A, Hummell DS, et al. Novel splicing, missense, and deletion mutations in seven adenosine deaminase-deficient patients with late/delayed onset of combined immunodeficiency disease. Contribution of genotype to phenotype. J Clin Invest 1993;92: 2291-302. (Pubitemid 23333535)
19. Jenkins T. Red-blood-cell adenosine deaminase deficiency in a "healthy" Kung individual. Lancet 1973;2:736.
20. Davies PM, McBride MB, Simmonds HA. An improved screening method for inherited disorders of purine and pyrimidine metabolism by HPLC. Adv Exp Med Biol 1991;309B:7-10.
21. Adam T, Friedecky D, Fairbanks LD, Sevcik J, Bartak P. Capillary electrophoresis for detection of inherited disorders of purine and pyrimidinemetabolism. Clin Chem 1999;45:2086-93.
22. Ito T, van Kuilenburg AB, Bootsma AH, Haasnoot AJ, van Cruchten A, Wada Y, et al. Rapid screening of highrisk patients for disorders of purine and pyrimidine metabolism using HPLC-electrospray tandem mass spectrometry of liquid urine or urine-soaked filter paper strips. Clin Chem 2000;46:445-52. (Pubitemid 30210714)
23. la Marca G, Casetta B, Malvagia S, Pasquini E, Innocenti M, Donati MA, et al. Implementing tandem mass spectrometry as a routine tool for characterizing the complete purine and pyrimidine metabolic profile in urine samples. J Mass Spectrom 2006;41:1442-52. (Pubitemid 44875654)
24. Azzari C, Massai C, Poggiolesi C, Indolfi G, Spagnolo G, De Luca M, et al. Cost of varicella-related hospitalisations in an Italian paediatric hospital: comparison with possible vaccination expenses. Curr Med Res Opin 2007;23:2945-54.
25. Demografia in cifre. Istituto Nazionale di Statistica, ISTAT. Available at: http://demo.istat.it/. Accessed April 29, 2011.